Personalis (NASDAQ:PSNL) Price Target Cut to $10.00 by Analysts at Morgan Stanley

Personalis (NASDAQ:PSNL) had its price objective cut by equities research analysts at Morgan Stanley from $11.00 to $10.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price would indicate a potential upside of 20.34% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Guggenheim increased their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. Finally, Needham & Company LLC lifted their target price on shares of Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Stock Performance

Personalis stock traded down $0.62 during mid-day trading on Thursday, reaching $8.31. 841,006 shares of the company were exchanged, compared to its average volume of 1,358,344. The firm has a market cap of $869.49 million, a P/E ratio of -9.13 and a beta of 2.02. The business has a fifty day moving average of $8.85 and a 200 day moving average of $8.07. Personalis has a 12-month low of $2.83 and a 12-month high of $11.50.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.05. The firm had revenue of $17.35 million during the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. Sell-side analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

A number of hedge funds and other institutional investors have recently made changes to their positions in PSNL. Caitong International Asset Management Co. Ltd lifted its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc purchased a new position in shares of Personalis during the 2nd quarter valued at about $30,000. International Assets Investment Management LLC purchased a new position in shares of Personalis during the 4th quarter valued at about $31,000. Ameritas Investment Partners Inc. acquired a new position in shares of Personalis in the 2nd quarter valued at about $34,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after buying an additional 5,177 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.